Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of “Buy” from Analysts
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been assigned a consensus recommendation of “Buy” from the fifteen analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $21.45.
A number of brokerages have issued reports on SCMP. UBS Group lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a research note on Friday, January 5th. B. Riley lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a research note on Tuesday, December 26th. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 31st. Maxim Group lowered Sucampo Pharmaceuticals to a “hold” rating in a research report on Monday, January 1st. Finally, Leerink Swann restated a “market perform” rating and set a $15.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Tuesday, January 2nd.
In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $17.95 on Friday. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $18.75. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The stock has a market capitalization of $849.02, a price-to-earnings ratio of -5.46, a price-to-earnings-growth ratio of 5.06 and a beta of 1.45.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. During the same quarter in the prior year, the business posted $0.30 EPS. Sucampo Pharmaceuticals’s revenue for the quarter was up 5.9% compared to the same quarter last year. equities analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.
WARNING: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://theolympiareport.com/2018/01/20/sucampo-pharmaceuticals-inc-scmp-receives-average-rating-of-buy-from-analysts.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.